Onyx Provides Detail On Frontline Strategy For Kyprolis
This article was originally published in The Pink Sheet Daily
Executive Summary
Onyx supplied details about its clinical plans to enable frontline approval for Kyprolis to treat multiple myeloma and to effectively compete against well-established proteasome inhibitor competitor Velcade. It also elaborated further on its pipeline plans and deal-making strategy at an analyst day on March 14.